- HK$36.60bn
- HK$21.56bn
- CNY17.70bn
Factbox: Major drugmakers turn to China for licensing deals
Factbox: Major drugmakers turn to China for licensing deals
Factbox: Major drugmakers turn to China for licensing deals
Factbox: US drugmakers turn to China for licensing deals
China's 3SBio H1 net profit falls on higher expenses
Biotech boom shows innovation is now made in China
Biotech boom shows innovation is now made in China
HK-listed 3SBIO slips on discounted share sale
Brief: 3SBio To Place 105.2 Million Shares
3SBio drops most in seven months on unit spin-off plans
Brief: 3Sbio Proposes Spin-Off And Listing Of Mandi Inc. On HKSE
BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial
Brief: 3Sbio Posts H1 Gross Margin Of 85.3%
Pfizer rises after annual profit forecast raise
Pfizer rises after annual profit forecast raise
Focus: US pharma bets big on China to snap up potential blockbuster drugs
HK-listed 3SBio hits 7-year peak on Pfizer licensing deal
Pfizer signs licensing deal worth about $6 billion with China's 3SBio for cancer drug (updated)
Pfizer signs up to $6 billion licensing deal with China's 3SBio for cancer drug